The short answer
Dense breast tissue looks white on a mammogram, the same color as cancer. It lowers how much mammography detects and modestly raises risk, and every US report now states your density.
Roughly 43 percent of women aged 40 to 74 have heterogeneously dense or extremely dense breasts, about 27.6 million people in the United States.
Density lowers detection. In women aged 40 to 49, mammography sensitivity falls from about 81 percent in non-dense breasts to about 63 percent in dense breasts; at ages 70 to 74 it falls from about 90 percent to about 57 percent.
Density is also a modest independent risk factor. Compared with average density, dense categories carry roughly 1.2 to 2.1 times the risk, well below the four- to six-fold figure sometimes quoted.
Since September 2024, FDA rules require every US mammogram report to tell you whether your breasts are dense or not dense.
Choose how you want to understand this
The full explanation.
What the density letter means
Since September 2024, FDA rules require every mammogram report in the United States to tell you whether your breasts are dense or not dense. Many people received that letter for the first time recently and read it as bad news about their health. It is not a diagnosis.
Breast density describes the mix of tissue visible on the image. Radiologists sort it into four BI-RADS categories: almost entirely fatty (about 10 percent of women), scattered fibroglandular (about 40 percent), heterogeneously dense (about 40 percent), and extremely dense (about 10 percent). The last two are what the word dense refers to. In an analysis of 1.5 million mammograms, 43.3 percent of women aged 40 to 74 fell into those categories, roughly 27.6 million people.
Density is largely inherited. It tends to fall with age and after menopause, and it rises with menopausal hormone therapy. Nothing you did caused it.
Why it matters twice
Dense tissue creates two separate problems, and they get blurred together constantly.
It hides cancer. On a mammogram, fat is dark and tumors are white. Dense fibroglandular tissue is also white. A cancer sitting inside it can be effectively invisible, the way a snowball is invisible against snow. This is called masking, and the numbers are substantial: in the AHRQ evidence review, sensitivity in women aged 40 to 49 fell from 81.2 percent in non-dense breasts to 63.3 percent in dense breasts. At ages 70 to 74 the drop was steeper, from 90.0 percent to 57.1 percent.
It raises risk on its own. Dense tissue is also biologically more likely to develop cancer, independent of what the mammogram can see. Here the honest number is smaller than the one often quoted. Comparisons of extremely dense to almost entirely fatty breasts can produce four- to six-fold figures, but almost no one is in the fatty category. Compared with average density, which is the comparison that matches most people, the increase is roughly 1.2 to 2.1 fold.
The cancers that get missed
A cancer diagnosed after a normal mammogram and before the next scheduled one is called an interval cancer. In the Dutch DENSE trial, women with extremely dense breasts screened with mammography alone had an interval cancer rate of 5.0 per 1,000 screenings. That is the concrete shape of the masking problem.
It is worth holding two things at once. Reduced sensitivity is not zero sensitivity. Mammography still finds most breast cancers in dense breasts, and the USPSTF estimates screening every other year from 40 to 74 averts roughly 7 to 8 breast cancer deaths per 1,000 women screened, and 9 to 11 among Black women.
What extra imaging does and costs
The DENSE trial randomized women with extremely dense breasts to supplemental MRI or mammography alone. MRI cut the interval cancer rate from 5.0 to 2.5 per 1,000 screenings. It also produced 79.8 false positives per 1,000 screenings, meaning most women called back because of the MRI did not have cancer, and many had a biopsy to establish that.
That is the whole trade in two sentences: fewer cancers surface between screens, considerably more people go through workups that end in nothing.
The USPSTF concluded that the evidence is insufficient to assess the balance of benefits and harms of supplemental ultrasound or MRI in women with dense breasts, and issued an I statement. An I statement means unknown, not no. It reflects that no trial has yet shown supplemental imaging reduces breast cancer deaths, which is a higher bar than reducing interval cancers.
A reasonable way to decide
Find out which of the four categories you are in, since heterogeneously dense and extremely dense are not equivalent and the evidence for supplemental MRI is strongest in the extremely dense group. Then get a formal risk estimate that includes family history, prior biopsies, and reproductive history, not density alone. A lifetime risk at or above roughly 20 percent moves you into high-risk guidelines where annual MRI is already recommended, independent of density.
Check coverage before scheduling. State insurance laws on supplemental imaging vary widely, and an ultrasound ordered as supplemental screening can be billed very differently from one ordered to investigate a finding.
And keep the basic rule intact: a lump, a change in skin or nipple, or focal pain that persists gets evaluated on its own, regardless of how recently a mammogram was read as normal.
Sources
Words to know
Tap any term to see what it means.
Common questions
My report says I have dense breasts. Is that a disease?
No. Breast density is a description of what your tissue looks like on a mammogram, not a diagnosis or an abnormality. Dense breasts have proportionally more fibrous and glandular tissue and less fat. It is common, it tends to decrease with age and after menopause, and it is influenced by genetics, body weight, and hormone use. About four in ten women who have mammograms fall into a dense category.
Why does density make cancer harder to see?
It is a contrast problem. Fat appears dark on a mammogram and tumors appear white, so a cancer in fatty tissue stands out. Dense fibroglandular tissue is also white, so a tumor sitting inside it can be hidden the way a snowball is hidden against snow. This is called masking, and it is why sensitivity drops as density rises rather than because the cancers themselves are different.
Should I get an ultrasound or MRI in addition to my mammogram?
There is no single right answer yet, which is what the USPSTF I statement means. Supplemental MRI clearly finds additional cancers and reduced interval cancers by half in the DENSE trial, but it also produced about 80 false positives per 1,000 screenings, most leading to further imaging or biopsy. Whether that trade is worth it depends on your density category, your other risk factors, your tolerance for false alarms, and what your insurance covers. It is a decision to make with your clinician rather than by rule.
Does having dense breasts mean a cancer found later will be worse?
Not on its own. Research summarized by NCI found that women with dense breasts who develop breast cancer have survival outcomes comparable to women with fatty breasts once other health factors and tumor characteristics are accounted for. Density affects how easily a cancer is seen, and it modestly affects how likely one is to occur. It is not a marker of more aggressive disease.
Should I stop having mammograms if they miss cancers in dense tissue?
No. Reduced sensitivity is not zero sensitivity, and mammography still finds the majority of cancers in dense breasts. The USPSTF recommends mammography every other year from 40 to 74 for all women, dense or not, and estimates it averts roughly 7 to 8 breast cancer deaths per 1,000 women screened. Density is a reason to ask about adding to your screening, not a reason to drop it.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the federal sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer Explained Editorial TeamSources last checked: 2026-07-30Last updated: 2026-07-30Next planned review: 2027-07-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source verified. This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source verified — This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share